First AD

Second AD

Metabolic Disorders and Delayed Diagnosis

Video content above is prompted by the following:

What are the potential cardiovascular and metabolic consequences associated with a delayed diagnosis and treatment of FCS? 

What are the possible long-term consequences and health risks?

Treatment of Familial Chylomicronemia Syndrome: A Multidisciplinary Approach

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels, leading to recurrent pancreatitis and other complications. Delayed diagnosis and treatment can exacerbate cardiovascular and metabolic consequences, including increased risk of atherosclerosis, cardiovascular disease, and metabolic syndrome. Long-term health risks involve persistent hypertriglyceridemia, which can cause chronic pancreatitis, diabetes, and liver disease. Early intervention is crucial to mitigate these risks, improve patient outcomes, and enhance quality of life by managing triglyceride levels and preventing severe complications.

Panelists discuss the potential cardiovascular and metabolic consequences of a delayed diagnosis and treatment of Familial Chylomicronemia Syndrome (FCS), emphasizing the long-term health risks, including an increased risk of acute pancreatitis, cardiovascular disease, and metabolic complications.